Earnings, deals and disclosures from Japan's listed materials & chemicals companies, in English.
The move: Shiseido’s first disclosed use of its April debt programme sets a ¥13bn corporate bond offering against a ¥300bn ceiling that runs until April 2028, with no prior drawdowns listed in the filing.
Up to 5mn shares, or 2.81% of stock, can be repurchased between August 2026 and August 2027, and Kansai Paint says the shares bought will be cancelled, though market conditions could prevent full execution.
The move: Kohjin Bio’s shareholders approved an audit and supervisory committee structure, split the top jobs between a chair and president, and signed off on a ¥10 per share dividend worth ¥51.1mn. Separately, Takahito Nakamura remained disclosed as the controlling shareholder with 53.91% of voting rights.
The move: Shiseido has moved to issue ¥13bn of corporate bonds, the first use of a ¥300bn shelf that became effective in April and runs until April 2028.
The move: Kansai Paint can repurchase up to 5mn shares, or 2.81 per cent of stock excluding treasury shares, between August 2026 and August 2027. The catch: it plans to cancel the repurchased stock, but says some or all orders may go unfilled depending on market conditions.
The move: Kohjin Bio adopted an audit-and-supervisory-committee model and split the top representative role between Takahito Nakamura as chairman and Yuichi Nakamura as president, while a same-day disclosure showed Takahito still controlled 53.91% of voting rights.
The move: Koei Chemical won 98.25% support for its share exchange with Sumitomo Chemical, pushing the deal past Koei's shareholder vote, but the filing adds no new timetable or deal economics.
The move: Shiseido has filed to issue ¥13bn of corporate bonds under a shelf that runs until April 2028, with the cover page showing a broader ¥300bn programme and no prior offerings under it.
The move: Kansai Paint can repurchase up to 5 million shares, or 2.81 per cent of stock outstanding, from August, and says the stock bought is planned for cancellation, making the programme a cleaner capital-efficiency signal than a standard treasury-stock authorisation.
The ¥19.1mn restricted-stock award uses treasury shares priced at the June 25 close, and transfer limits lift only after executive-officer recipients stay in post through June 30, 2027. For subsidiary directors, the cutoff is the next annual shareholders' meeting date scheduled for June 2027.
Katakura says Zen-Noh and Marubeni exert equivalent influence as shareholders, but disclosed trade flows show far larger business ties to the cooperative federation.
The Japanese producer will fund the plant build-out itself under a 10-year deal with Select Water Solutions, aiming to establish a new US iodine supply source and reach about 3,000 tonnes a year from the project by 2030.
Management says ROE in the year to March 2026 was 6.87% against a PBR of 0.80x, above its rough 6% equity-cost estimate but still short of its 8% goal. The company is prioritising investment over a cosmetic fix, targeting operating profit of ¥2.4bn and net profit of ¥1.6bn by 2028 while saying ROE is only expected to improve to 7.6% during the current plan.
Sales rose to ¥19.48bn and ordinary income to ¥894mn, while parent profit came in at ¥791mn. That is not a first return to profit - the company was also profitable a year earlier - but it does keep plenty of distance from the ¥1.01bn loss posted two years ago.
For the year to March 2026, sales rose to ¥745.41bn and ordinary income to ¥54.33bn. The same summary series puts parent profit at ¥62.46bn, net assets at ¥474.63bn and total assets at ¥794.48bn. The filing mixes historical rows together, so some archaeology is required.
Sales rose to ¥29.69bn, ordinary income to ¥2.77bn and parent profit to ¥1.99bn, and shareholders approved an ¥85-a-share dividend effective June 24. Clean manufacturing snapshot, no grand theory required.
Toyo Gosei reported sales of ¥41.96bn for the year to March 2026, up from ¥38.67bn, but ordinary income slipped to ¥3.59bn from ¥4.00bn and net income fell to ¥2.69bn from ¥3.28bn. The annual dividend was cut to ¥40 from ¥45, even as the equity-to-asset ratio improved to 41.0% from 37.7%, leaving a familiar mixed message: sturdier balance sheet, thinner earnings.
Sales fell to ¥41.07bn from ¥43.13bn, but ordinary income rose to ¥10.82bn from ¥9.68bn and net assets stood at ¥91.27bn. The balance sheet still looks notably thick.
The company appointed its representative director, president and group CEO as chairman of the board effective June 20, and a same-day duties notice says he also keeps risk management and research oversight. That makes the governance change a clear concentration of top roles, not a change of face.
Resona Bank extended the unsecured facility for one year from June 30, but Liberta still has to keep consolidated net assets at 75% or more of the prior-year level and avoid an operating loss. The filing does not disclose how much of the line is drawn.
Fujikura raised first-half operating profit guidance to ¥174bn from ¥92bn and full-year operating profit to ¥310bn from ¥211bn. The company tied the move to unexpected optical-component projects from hyperscalers, selling-price increases and a milder hydrogen shortage impact in its information and telecommunications business. The scale is hard to ignore: first-half sales guidance rose to ¥778bn from ¥594bn, while full-year revenue moved to ¥1.462tn from ¥1.243tn. Fujikura says pricing and the easing of hydrogen constraints should continue into the second half, though it did not say whether the surprise hyperscaler orders will recur at the same pace.
Full-year sales guidance falls to ¥30.0bn from ¥31.0bn and operating profit to ¥2.7bn from ¥3.1bn because Daiei Electronics will leave consolidation. Net income guidance rises to ¥3.0bn from ¥2.0bn because the subsidiary sale creates an extraordinary gain, which is a very different sort of good news.
Kumi Chemical now expects first-half revenue of ¥102,900 million and operating profit of ¥10,400 million, well above its December forecast, citing pulled-forward agrochemical shipments and solid chemical-product sales. But a separate notice said a subsidiary's chlorination business will record a ¥514 million impairment and a ¥907 million structural reform cost in the February-to-April quarter. The company left its full-year outlook unchanged while assessing Middle East risks. So the operating story improved sharply, but reported profit still comes with attachments.